Hua Medicine 3
Patient First: Clinical Trials in China
"Patient First, innovation driven, Novel medicine" is the mission of Hua Medicine, one of China’s leading biotech companies. While focusing on building up a sound scientific foundation for their innovative medicine, Hua has worked closely with leading physicians and top clinical study organizations across China to to ensure a high standard & high quality of drug development.
Dorzagliatin, Hua's next generation Glucokinase Activator, is currently in Phase 3 cliniucal trials across China. Conducting a high standard and high-quality study across China's diverse health landscape in order to deliver value to patients is not only the commitment of Hua medicine, but the belief of Hua’s clinical study team. Led by leading clinicians in clinical practice across the country, Hua’s study team is making every effort to strengthen the quality of its trials.
Starting in China, the ultimate goal for Hua and its partners is to develop and manufacture high standard & high-quality medicine to benefit Type 2 Diabetes patients all over the world, and these Phase 3 thrials are hopefully just the start.
Dorzagliatin is a novel drug. It has a different clinical profile to previous Glucokinase Activators. One of Dorzagliatin’s unique features is that, at the molecular level, it shows very hypoglycae enzyme kinetics, which makes it a glucose-dependent Glucokinase Activators, avoiding hypoglycaemia. Phase 2 studies have emphasized it’s potent and sustained efficacy as well as safety profiles, including the low incidence of hypoglycaemia, no lipid changes, no elevated liver enzyme, and no cardiovascular adverse effects.